Oasmia will use some of the proceeds from the rights issue in November/December to pay accrued interest and a part of the original loan from Nxt2b of MSEK 105 that is due December 31, 2014. The new loan amounts to MSEK 87 and is due December 31, 2015, and the interest for the period 2015-01-01 to 2015-12-31 is set to 8,5%. Nxt2b is Oasmia’s second largest owner after Alseco International S.A. with approx. 20% of the shares in the company.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, compared to current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. Product development is based on in-house research within nanotechnology and proprietary patents. Oasmia Pharmaceutical AB’s shares, ISIN SE0000722365, are listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).